AQR Capital Management LLC cut its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.9% during the first quarter, Holdings Channel reports. The fund owned 443,802 shares of the medical instruments supplier’s stock after selling 13,310 shares during the period. AQR Capital Management LLC’s holdings in Becton, Dickinson and were worth $81,411,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in BDX. BlackRock Inc. increased its position in Becton, Dickinson and by 2,427.8% in the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after buying an additional 15,887,611 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Becton, Dickinson and by 5.3% in the first quarter. Vanguard Group Inc. now owns 15,902,168 shares of the medical instruments supplier’s stock worth $2,917,094,000 after buying an additional 796,034 shares during the period. Cantillon Capital Management LLC boosted its stake in shares of Becton, Dickinson and by 30.3% in the first quarter. Cantillon Capital Management LLC now owns 1,344,427 shares of the medical instruments supplier’s stock worth $246,622,000 after buying an additional 312,926 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Becton, Dickinson and by 6.5% in the first quarter. JPMorgan Chase & Co. now owns 3,967,843 shares of the medical instruments supplier’s stock worth $727,863,000 after buying an additional 242,081 shares during the period. Finally, Prudential Financial Inc. boosted its stake in shares of Becton, Dickinson and by 34.0% in the first quarter. Prudential Financial Inc. now owns 930,445 shares of the medical instruments supplier’s stock worth $170,681,000 after buying an additional 236,280 shares during the period. 75.71% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company (BDX) traded up 0.9235% during midday trading on Friday, hitting $200.0506. The stock had a trading volume of 291,062 shares. The firm has a 50 day moving average price of $198.75 and a 200 day moving average price of $187.49. The stock has a market cap of $45.52 billion, a PE ratio of 57.9353 and a beta of 1.05. Becton, Dickinson and Company has a one year low of $161.29 and a one year high of $206.63.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. During the same period in the previous year, the company posted $2.35 EPS. The company’s quarterly revenue was down 5.1% compared to the same quarter last year. Equities analysts expect that Becton, Dickinson and Company will post $9.46 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be given a dividend of $0.73 per share. This represents a $2.92 annualized dividend and a yield of 1.47%. The ex-dividend date of this dividend is Thursday, September 7th. Becton, Dickinson and’s payout ratio is 83.43%.

TRADEMARK VIOLATION WARNING: “Becton, Dickinson and Company (NYSE:BDX) Shares Sold by AQR Capital Management LLC” was posted by Daily Political and is the property of of Daily Political. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.dailypolitical.com/2017/08/11/becton-dickinson-and-company-nysebdx-shares-sold-by-aqr-capital-management-llc.html.

A number of equities research analysts have commented on BDX shares. BidaskClub cut Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Zacks Investment Research cut Becton, Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, May 4th. Bank of America Corporation reiterated a “buy” rating and set a $225.00 target price (up previously from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. Stifel Nicolaus reiterated a “buy” rating on shares of Becton, Dickinson and in a report on Wednesday. Finally, Raymond James Financial, Inc. upgraded Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and lowered their target price for the company from $210.00 to $180.00 in a report on Friday, June 30th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Becton, Dickinson and currently has a consensus rating of “Buy” and a consensus price target of $195.79.

In other Becton, Dickinson and news, insider Thomas E. Polen, Jr. sold 5,971 shares of Becton, Dickinson and stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the transaction, the insider now directly owns 12,861 shares in the company, valued at approximately $2,538,890.01. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Jeffrey S. Sherman sold 28,765 shares of Becton, Dickinson and stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $185.98, for a total transaction of $5,349,714.70. Following the transaction, the vice president now owns 70,821 shares in the company, valued at $13,171,289.58. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.